Hepatitis B Virus infection is the major health problem throughout the world affecting more than 350 million people who are carriers of this virus that can cause chronic hepatitis, liver cirrhosis and hepato cellular carcinoma.
Failed HBV Treatment :
Several anti-viral those are currently available for the treatment of HBV which include IFN alpha, Lamuvidine, Entecavir, Telbibudine, and Tenofovir.
Interferon therapy has limited efficacy, slow-acting, and frequently causes adverse effects. Undesirable side effects of interferon treatment are found such as fever, malaise, fatigue, depression, hair loss, neutropenia, and thrombocytopenia.
On the other hand, the side effects of Tenofovir are no less than Interferon. The common side effects include fever, pain, diarrhea, vomiting, depressed mood, rashes, insomnia. Moreover, the anti-viral drug and Interferon are expensive. Moreover, if the patient drops the Tenofovir medication even for 48 hours the HBV viral load elevates to 103.
HOO-IMM PLUS, a herbal composite formula ensures effective action on multiple targets simultaneously anti-HBV, anti-Hepatocellular Carcinoma (HCC) and Hepatoprotective.
Biomarker or Test protocol involved in the anti-hbv treatment with Hooimm plus:-
- HBV Serological markers which include HBsAg & HBeAg Elisa.
- Serum Alanine Aminotransferase (ALT) or Serum glutamic pyruvic transaminase (SGPT) & Aspartate Aminotransferase (AST) or SGOT.
- HBV DNA Quantification-Viral Load.
Note: Quantification of HBV DNA reflects the viral load which plays a critical role in determining the phase of infection, deciding the treatment and determining the response to anti-viral treatment. This test is highly recommended in Chronic HBV- World Health Organization (WHO)
The anti-HBV activity of HOO-IMM PLUS has been reported by many Ayush clinicians in India and pharmacist from Africa. HOO-IMM PLUS has been extensively clinically studied against HBV on the inhibition of HBsAg secretion PLC/PRF/5 Cells and also the inhibition of Hepato carcinoma in HepG2 cell line. Clinically patients receiving Hooimm plus reported Target not detected in HBV DNA Quantitative.
Anti-Hepatocellular Carcinoma (HCC)
The HOO-IMM PLUS constitute curcumin molecule which has been proven a star key molecule in preventing hepatocellular carcinoma. Many research have been done on curcumin suggesting that it inhibits proliferation induces apoptosis, potentiate attenuate ROS. But the poor systemic absorption of curcumin is major obstacle for its efficacy. Here we have a unique extraction procedure for curcuma longa which yields curcumin with high degree bioavailaibility and along with other herbal extract formulation that improves the gut absorption of curcumin.
The treatment prognosis reports a normal level of the routine test of Serum Alanine Aminotransferase (ALT) or serum glutamic pyruvic transaminase (SGPT) and Aspartate Aminotransferase (AST).
AST and SGPT is a blood test that checks for liver damage. SGPT and AST levels in the blood rise if your liver is damaged.
Each Dose of 750 MG
|Muleti Ext||Glycyrrhiza glabra||75 MG|
|Bhui Amlaki Ext||Phyllanthus Niruri||75 MG|
|Harda Ext||Terminalia Chebula||75 MG|
|Bhojpatra Ext||Betula Utilis||75 MG|
|Punnaga Ext||Callophyllum Inophyllum||75 MG|
|Haldi Ext||Curcuma Longa||75 MG|
|Kalmegh Ext||Andrographis Paniculata||75 MG|
|Karela Beej Ext||Memordica Charantia||75 MG|
|Bichu Buti Ext||Urtica dioica||75 MG|
|Nirgundi Ext||Justica Gendarussa||75 MG|
Frequently Asked Questions
Brief Detail on HBV
Why HBV treatment is highly recommended?
HBV infection leads to severe diseases, including hepatitis, liver cirrhosis, and hepatocellular carcinoma.
HBV has also been suggested to be involved in the development of pancreatic
Approximately 4 crore individuals are infected with HBV, and more than 1.5 lakh people with HBV infection die every year as a result of end-stage liver disease and hepatocellular carcinoma in India.
Most of the mortality due to Viral Hepatitis is attributed to Hepatitis B and C,
which are also known as silent killers as more than 80% of the infected aren’t
aware of their infection.
Hepatitis B and C infections can remain asymptomatic for years, even decades,
slowly damaging the liver.
Fighting hepatitis is difficult because both hepatitis B and C are chronic
infections that often remain dormant in the body for years before damaging the
liver. Liver cirrhosis and liver cancer are the common culmination of these chronic
infections. Most people infected with the virus are not aware of their
Chronic HBV infection accounts for 40-50% of hepatocellular carcinoma (HCC)
and 20-30% cases of liver cirrhosis while chronic HCV infection accounts for 12-
32% of HCC and 12-20% of liver cirrhosis in the country.